101
|
Chen T, Li C, Li Y, Yi X, Lee SMY, Zheng Y. Oral Delivery of a Nanocrystal Formulation of Schisantherin A with Improved Bioavailability and Brain Delivery for the Treatment of Parkinson’s Disease. Mol Pharm 2016; 13:3864-3875. [DOI: 10.1021/acs.molpharmaceut.6b00644] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Tongkai Chen
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau, China
| | - Chuwen Li
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau, China
| | - Ye Li
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau, China
| | - Xiang Yi
- Division
of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Simon Ming-Yuen Lee
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau, China
| | - Ying Zheng
- State
Key Laboratory of Quality Research in Chinese Medicine, Institute
of Chinese Medical Sciences, University of Macau, Macau, China
| |
Collapse
|
102
|
Suri GS, Kaur A, Sen T. A recent trend of drug-nanoparticles in suspension for the application in drug delivery. Nanomedicine (Lond) 2016; 11:2861-2876. [PMID: 27759500 DOI: 10.2217/nnm-2016-0238] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Persistent development in nanomedicine has enabled successful nanosizing of most drug samples which, in turn, imparts remarkable properties to the drugs such as enhanced solubility and bioavailability for the applications in drug delivery. In this context, several review articles are available in scientific domain covering inorganic nanoparticles such as Au, Ag, SPIONs, Qdots, carbon nanotubes and graphene; however, this review covers the development of drug nanoparticles together with their possibilities and limitation from fabrication (bottom up vs top down) to application in drug delivery during the last 5 years. In addition, some distinguished studies and novel drug particles are presented in order to contribute significantly toward the understanding of drug nanocrystals and its use in drug delivery.
Collapse
Affiliation(s)
- Gurpreet S Suri
- Nano-biomaterials Research Group, School of Physical Sciences & Computing, Centre of Materials Sciences, University of Central Lancashire, Preston, PR1 2HE, UK
| | - Amritvir Kaur
- Nano-biomaterials Research Group, School of Physical Sciences & Computing, Centre of Materials Sciences, University of Central Lancashire, Preston, PR1 2HE, UK
| | - Tapas Sen
- Nano-biomaterials Research Group, School of Physical Sciences & Computing, Centre of Materials Sciences, University of Central Lancashire, Preston, PR1 2HE, UK
| |
Collapse
|
103
|
Choi JS, Park JS. Effects of paclitaxel nanocrystals surface charge on cell internalization. Eur J Pharm Sci 2016; 93:90-6. [DOI: 10.1016/j.ejps.2016.08.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Revised: 08/01/2016] [Accepted: 08/06/2016] [Indexed: 11/24/2022]
|
104
|
Tuomela A, Saarinen J, Strachan CJ, Hirvonen J, Peltonen L. Production, applications and in vivo fate of drug nanocrystals. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2016.02.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
105
|
Development and evaluation of decorated aceclofenac nanocrystals. Colloids Surf B Biointerfaces 2016; 143:206-212. [DOI: 10.1016/j.colsurfb.2016.03.022] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 02/18/2016] [Accepted: 03/07/2016] [Indexed: 01/21/2023]
|
106
|
Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J Control Release 2016; 240:504-526. [PMID: 27292178 DOI: 10.1016/j.jconrel.2016.06.016] [Citation(s) in RCA: 258] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Revised: 06/07/2016] [Accepted: 06/08/2016] [Indexed: 02/06/2023]
Abstract
The oral route is a preferred method of drug administration, though achieving effective drug delivery and minimizing off-target side effects is often challenging. Formulation into nanoparticles can improve drug stability in the harsh gastrointestinal (GI) tract environment, providing opportunities for targeting specific sites in the GI tract, increasing drug solubility and bioavailability, and providing sustained release in the GI tract. However, the unique and diverse physiology throughout the GI tract, including wide variation in pH, mucus that varies in thickness and structure, numerous cell types, and various physiological functions are both a barrier to effective delivery and an opportunity for nanoparticle design. Here, nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed. We then review new methods for evaluating oral nanoparticle formulations, including a short commentary on data interpretation and translation. Finally, the state-of-the-art in preclinical targeted nanoparticle design is reviewed.
Collapse
Affiliation(s)
- Abhijit A Date
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA
| | - Justin Hanes
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA; Departments of Biomedical Engineering, Environmental and Health Sciences, Oncology, Neurosurgery, Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Laura M Ensign
- The Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N Broadway, Baltimore, MD 21231, USA; Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
| |
Collapse
|
107
|
Evaluation of TPGS-modified thermo-sensitive Pluronic PF127 hydrogel as a potential carrier to reverse the resistance of P-gp-overexpressing SMMC-7721 cell lines. Colloids Surf B Biointerfaces 2016; 140:307-316. [DOI: 10.1016/j.colsurfb.2015.12.057] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2015] [Revised: 12/24/2015] [Accepted: 12/30/2015] [Indexed: 12/22/2022]
|
108
|
Mechanistic investigation of biopharmaceutic and pharmacokinetic characteristics of surface engineering of satranidazole nanocrystals. Eur J Pharm Biopharm 2016; 100:109-18. [DOI: 10.1016/j.ejpb.2015.12.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 12/21/2015] [Accepted: 12/23/2015] [Indexed: 12/14/2022]
|
109
|
Naturally occurring proteinaceous nanoparticles in Coptidis Rhizoma extract act as concentration-dependent carriers that facilitate berberine absorption. Sci Rep 2016; 6:20110. [PMID: 26822920 PMCID: PMC4731763 DOI: 10.1038/srep20110] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 12/24/2015] [Indexed: 12/19/2022] Open
Abstract
Pharmacological activities of some natural products diminish and even disappear after purification. In this study, we explored the mechanisms underlying the decrease of acute oral toxicity of Coptidis Rhizoma extract after purification. The water solubility, in vitro absorption, and plasma exposure of berberine (the major active compound) in the Coptidis Rhizoma extract were much better than those of pure berberine. Scanning electron microscopy, laser scanning confocal microscopy (LSCM), and dynamic light scattering experiments confirmed that nanoparticles attached to very fine precipitates existed in the aqueous extract solution. The LSCM experiment showed that the precipitates were absorbed with the particles by the mouse intestine. High-speed centrifugation of the extract could not remove the nanoparticles and did not influence plasma exposure or acute oral toxicity. However, after extract dilution, the attached precipitates vanished, although the nanoparticles were preserved, and there were no differences in the acute oral toxicity and plasma exposure between the extract and pure berberine. The nanoparticles were then purified and identified as proteinaceous. Furthermore, they could absorb co-dissolved berberine. Our results indicate that naturally occurring proteinaceous nanoparticles in Coptidis Rhizoma extract act as concentration-dependent carriers that facilitate berberine absorption. These findings should inspire related studies in other natural products.
Collapse
|
110
|
Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release 2015; 223:137-156. [PMID: 26739547 DOI: 10.1016/j.jconrel.2015.12.047] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 12/23/2015] [Accepted: 12/23/2015] [Indexed: 01/12/2023]
Abstract
Psychiatric illnesses are a leading cause of disability and morbidity globally. However, the preferred orally dosed pharmacological treatment options available for depression, anxiety and schizophrenia are often limited by factors such as low drug aqueous solubility, food effects, high hepatic first-pass metabolism effects and short half-lives. Furthermore, the discovery and development of more effective psychotropic agents has stalled in recent times, with the majority of new drugs reaching the market offering similar efficacy, but suffering from the same oral delivery concerns. As such, the application of nanomedicine formulation approaches to currently available drugs is a viable option for optimizing oral drug delivery and maximizing treatment efficacy. This review focuses on the various delivery challenges encountered by psychotropic drugs, and the ability of nanomedicine formulation strategies to overcome these. Specifically, we critically review proof of concept in vitro and in vivo studies of nanoemulsions/microemulsions, solid lipid nanoparticles, dendrimers, polymeric micelles, nanoparticles of biodegradable polymers and nanosuspensions, and provide new insight into the various mechanisms for improved drug performance. The advantages and limitations of current oral nanomedicine approaches for psychotropic drugs are discussed, which will provide guidance for future research directions and assist in fostering the translation of such delivery systems to the clinical setting. Accordingly, emphasis has been placed on correlating the in vitro/in vivo performance of these nanomedicine approaches with their potential clinical outcomes and benefits for patients.
Collapse
Affiliation(s)
- Tahnee J Dening
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Shasha Rao
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Nicky Thomas
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Clive A Prestidge
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia.
| |
Collapse
|
111
|
McClements DJ, Zou L, Zhang R, Salvia-Trujillo L, Kumosani T, Xiao H. Enhancing Nutraceutical Performance Using Excipient Foods: Designing Food Structures and Compositions to Increase Bioavailability. Compr Rev Food Sci Food Saf 2015. [DOI: 10.1111/1541-4337.12170] [Citation(s) in RCA: 89] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- David Julian McClements
- Biopolymers and Colloids Laboratory, Dept. of Food Science; Univ. of Massachusetts Amherst; Amherst Mass 01003 U.S.A
- Biochemistry Dept., Faculty of Science, Production of Bioproducts for Industrial Applications Research Group and Experimental Biochemistry Unit; King Fahd Medical Research Center, King Abdulaziz Univ; Jeddah Saudi Arabia
| | - Liqiang Zou
- State Key Laboratory of Food Science and Technology; Nanchang Univ; Nanchang, No. 235 Nanjing East Road Nanchang 330047 Jiangxi China
| | - Ruojie Zhang
- State Key Laboratory of Food Science and Technology; Nanchang Univ; Nanchang, No. 235 Nanjing East Road Nanchang 330047 Jiangxi China
| | - Laura Salvia-Trujillo
- State Key Laboratory of Food Science and Technology; Nanchang Univ; Nanchang, No. 235 Nanjing East Road Nanchang 330047 Jiangxi China
| | - Taha Kumosani
- Biochemistry Dept., Faculty of Science, Production of Bioproducts for Industrial Applications Research Group and Experimental Biochemistry Unit; King Fahd Medical Research Center, King Abdulaziz Univ; Jeddah Saudi Arabia
| | - Hang Xiao
- Biopolymers and Colloids Laboratory, Dept. of Food Science; Univ. of Massachusetts Amherst; Amherst Mass 01003 U.S.A
| |
Collapse
|
112
|
Sharma S, Verma A, Pandey G, Mittapelly N, Mishra PR. Investigating the role of Pluronic-g-Cationic polyelectrolyte as functional stabilizer for nanocrystals: Impact on Paclitaxel oral bioavailability and tumor growth. Acta Biomater 2015; 26:169-83. [PMID: 26265061 DOI: 10.1016/j.actbio.2015.08.005] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 07/31/2015] [Accepted: 08/07/2015] [Indexed: 12/20/2022]
Abstract
Paclitaxel (PTX) is a potent anticancer drug which suffers limitations of extremely low oral bioavailability due to low solubility, rapid metabolism and efflux by P-gp transporters. The main objective of this study was to overcome the limitation of PTX by designing delivery systems that can enhance the absorption using multiple pathways. A novel Pluronic-grafted chitosan (Pl-g-CH) copolymer was developed and employed as a functional stabilizer for nanocrystals (NCs) and hypothesized that it would improve PTX absorption by several mechanisms and pathways. Pl-g-CH was synthesized and characterized using (1)H NMR and then used as a stabilizer during nanocrystal development. To establish our proof of concept the optimized formulation having a particle size 192.7 ± 9.2 nm and zeta potential (+) 38.8 ± 3.12 mV was studied extensively on in vitro Caco-2 model. It was observed that nanocrystals rendered higher PTX accumulation inside the cell than Taxol™. P-gp inhibitory potential of Pl-g-CH was proved by flow cytometry and fluorescence microscopy where the much enhanced fluorescence intensity of Rhodamine 123 (Rho-123, P-gp substrate) was observed in the presence of Pl-g-CH. In addition, a significant decrease in Trans Epithelial Electrical Resistance (TEER) of Caco-2 cell monolayers was observed with nanocrystals as well as with Taxol™ (in the presence of free Pl-g-CH compared to only Taxol™). This supports the role of the stabilizer in reversible opening of tight junctions between cells which can allow paracellular transport of drug. The in vivo results were in complete corroboration with in vitro results. Nanocrystals resulted in much enhanced absorption with 12.6-fold improvement in relative bioavailability to that of Taxol™. Concomitantly efficacy data in B16 F10 murine melanoma model also showed a significant reduction in tumor growth with nanocrystals compared to Taxol™ and control. Based on the results it can be suggested that nanocrystals with functional stabilizers can be a promising approach for the oral delivery of anticancer drugs which are P-gp substrates STATEMENT OF SIGNIFICANCE Nanocrystals are currently one of the most explored novel drug delivery systems especially for oral delivery of drugs because of ease in synthesis and high drug loading. But their use is still limited for oral delivery of anticancer drugs which are P-gp substrates. This particular study aims at widening the scope of nanocrystals by using a functional stabilizer which participates in enhancing the oral absorption of anticancer drugs and controlling the tumor growth.
Collapse
Affiliation(s)
- Shweta Sharma
- Division of Pharmaceutics, CSIR-Central Drug Research Institute (Council of Scientific and Industrial Research), B 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, U.P. 226031, India
| | - Ashwni Verma
- Division of Pharmaceutics, CSIR-Central Drug Research Institute (Council of Scientific and Industrial Research), B 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, U.P. 226031, India
| | - Gitu Pandey
- Division of Pharmaceutics, CSIR-Central Drug Research Institute (Council of Scientific and Industrial Research), B 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, U.P. 226031, India
| | - Naresh Mittapelly
- Division of Pharmaceutics, CSIR-Central Drug Research Institute (Council of Scientific and Industrial Research), B 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, U.P. 226031, India
| | - Prabhat Ranjan Mishra
- Division of Pharmaceutics, CSIR-Central Drug Research Institute (Council of Scientific and Industrial Research), B 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, U.P. 226031, India.
| |
Collapse
|
113
|
Barbosa SF, Takatsuka T, Tavares GD, Araújo GLB, Wang H, Vehring R, Löbenberg R, Bou-Chacra NA. Physical-chemical properties of furosemide nanocrystals developed using rotation revolution mixer. Pharm Dev Technol 2015; 21:812-822. [PMID: 27825283 DOI: 10.3109/10837450.2015.1063650] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Recently, several approaches have been reported to improve the dissolution rate and bioavailability of furosemide, a class IV drug. However, to the best of our knowledge, none of them proposed nanocrystals. In the last decade, nanocrystals successfully addressed solubility issues by increasing surface area and saturation solubility, both leading to an increase in the dissolution rate of poor water soluble drugs. The preparation of furosemide nanocrystals was by a rotation revolution mixer method. Size distribution and morphology were performed using laser diffraction and scanning electron microscopy, respectively. In addition, differential scanning calorimetry, thermogravimetry, X-ray powder diffraction (XRD) and low frequency shift-Raman spectroscopy allowed investigating the thermal properties and crystalline state. Solubility saturation and intrinsic dissolution rate (IDR) studies were conducted. The thermal analysis revealed lower melting range for the nanocrystals comparing to furosemide. Moreover, a slight crystalline structure change to the amorphous state was observed by XRD and confirmed by low frequency shift Raman. The particle size was reduced to 231 nm with a polydispersity index of 0.232, a 30-fold reduction from the original powder. Finally, the saturation solubility and IDR showed a significant increase. Furosemide nanocrystals showed potential for development of innovative formulations as an alternative to the commercial products.
Collapse
Affiliation(s)
- Sávio Fujita Barbosa
- a Faculty of Pharmaceutical Sciences , University of São Paulo , São Paulo , São Paulo , Brazil
| | | | - Guilherme Diniz Tavares
- c Course of Pharmacy, Department of Biochemistry , Institute of Biology, State University of Campinas , Campinas , São Paulo , Brazil , and
| | | | - Hui Wang
- d Faculty of Pharmacy and Pharmaceutical Sciences , Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta , Edmonton , Alberta , Canada
| | - Reinhard Vehring
- d Faculty of Pharmacy and Pharmaceutical Sciences , Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta , Edmonton , Alberta , Canada
| | - Raimar Löbenberg
- d Faculty of Pharmacy and Pharmaceutical Sciences , Katz Group-Rexall Centre for Pharmacy & Health Research, University of Alberta , Edmonton , Alberta , Canada
| | - Nádia Araci Bou-Chacra
- a Faculty of Pharmaceutical Sciences , University of São Paulo , São Paulo , São Paulo , Brazil
| |
Collapse
|
114
|
Lu Y, Chen Y, Gemeinhart RA, Wu W, Li T. Developing nanocrystals for cancer treatment. Nanomedicine (Lond) 2015; 10:2537-52. [PMID: 26293310 DOI: 10.2217/nnm.15.73] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Nanocrystals are carrier-free solid drug particles that are sized in the nanometer range and have crystalline characteristics. Due to high drug loading (as high as 100%) - free of organic solvents or solubilizing chemicals - nanocrystals have become attractive in the field of drug delivery for cancer treatment. Top-down and bottom-up approaches have been developed for preparing anticancer nanocrystals. In this review, preparation methods and in vivo performance of anticancer nanocrystals are discussed first, followed by an introduction of hybrid nanocrystals in cancer theranostics.
Collapse
Affiliation(s)
- Yi Lu
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.,Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, 201203, China
| | - Yan Chen
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.,Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai, 200433, China
| | - Richard A Gemeinhart
- Departments of Biopharmaceutical Sciences, Bioengineering & Ophthalmology & Visual Sciences, The University of Illinois, Chicago, IL 60612, USA
| | - Wei Wu
- Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai, 201203, China
| | - Tonglei Li
- Department of Industrial & Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA
| |
Collapse
|
115
|
Turovsky T, Khalfin R, Kababya S, Schmidt A, Barenholz Y, Danino D. Celecoxib Encapsulation in β-Casein Micelles: Structure, Interactions, and Conformation. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2015; 31:7183-7192. [PMID: 26068530 DOI: 10.1021/acs.langmuir.5b01397] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
β-Casein is a 24 kDa natural protein that has an open conformation and almost no folded or secondary structure, and thus is classified as an intrinsically unstructured protein. At neutral pH, β-casein has an amphiphilic character. Therefore, in contrast to most unstructured proteins that remain monomeric in solution, β-casein self-assembles into well-defined core-shell micelles. We recently developed these micelles as potential carriers for oral administration of poorly water-soluble pharmaceuticals, using celecoxib as a model drug. Herein we present deep and precise insight into the physicochemical characteristics of the protein-drug formulation, both in bulk solution and in dry form, emphasizing drug conformation, packing properties and aggregation state. In addition, the formulation is extensively studied in terms of structure and morphology, protein/drug interactions and physical stability. Particularly, NMR measurements indicated strong drug-protein interactions and noncrystalline drug conformation, which is expected to improve drug solubility and bioavailability. Small-angle X-ray scattering (SAXS) and cryogenic transmission electron microscopy (cryo-TEM) were combined for nanostructural characterization, proving that drug-protein interactions lead to well-defined spheroidal micelles that become puffier and denser upon drug loading. Dynamice light scattering (DLS), turbidity measurements, and visual observations complemented the analysis for determining formulation structure, interactions, and stability. Additionally, it was shown that the loaded micelles retain their properties through freeze-drying and rehydration, providing long-term physical and chemical stability. Altogether, the formulation seems greatly promising for oral drug delivery.
Collapse
Affiliation(s)
- Tanya Turovsky
- †Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Rafail Khalfin
- ‡Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Shifi Kababya
- §Shulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Asher Schmidt
- §Shulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| | - Yechezkel Barenholz
- ∥Laboratory of Membrane and Liposome Research, IMRIC, the Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
| | - Dganit Danino
- †Russell Berrie Nanotechnology Institute, Technion - Israel Institute of Technology, Haifa 3200003, Israel
- ⊥Department of Biotechnology and Food Engineering, Technion - Israel Institute of Technology, Haifa 3200003, Israel
| |
Collapse
|
116
|
Friberg S, Nyström AM. Nanotechnology in the war against cancer: new arms against an old enemy – a clinical view. Future Oncol 2015; 11:1961-75. [DOI: 10.2217/fon.15.91] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
ABSTRACT Clinical oncology is facing a paradigm shift. A new treatment philosophy is emerging and new targets are appearing that require new active agents. The medical use of nanotechnology – nanomedicine – holds several promising possibilities in the war against cancer. Some of these include: new formats for old drugs, that is, increasing efficacy while diminishing side effects; and new administration routes – that is, dermal, oral and pulmonary. In this overview, we describe some nanoparticles and their medical uses as well as highlight advantages of nanoparticles compared with conventional pharmaceuticals. We also point to some of the many technical challenges and potential risks with using nanotechnology for oncological applications.
Collapse
Affiliation(s)
- Sten Friberg
- Swedish Medical Nanoscience Center, Department of Neuroscience, Retzius väg 8, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Andreas M Nyström
- Institute of Environmental Medicine, Nobels väg 13, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| |
Collapse
|
117
|
Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2015; 2015:239749. [PMID: 25866534 PMCID: PMC4381853 DOI: 10.1155/2015/239749] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Accepted: 09/11/2014] [Indexed: 11/21/2022]
Abstract
Berberine (Ber), an isoquinoline derivative alkaloid and active ingredient of Coptis, has been demonstrated to possess antidiabetic activities. However its low oral bioavailability restricts its clinical application. In this report, Ber nanosuspension (Ber-NS) composed of Ber and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared by high pressure homogenization technique. Antidiabetic effects of Ber-NS relative to efficacy of bulk Ber were evaluated in streptozotocin (STZ) induced diabetic C57BL/6 mice. The particle size and zeta potential of Ber-NS were 73.1 ± 3.7 nm and 6.99 ± 0.17 mV, respectively. Ber-NS (50 mg/kg) treatment via oral gavage for 8 weeks resulted in a superior hypoglycemic and total cholesterol (TC) and body weight reduction effects compared to an equivalent dose of bulk Ber and metformin (Met, 300 mg/kg). These data indicate that a low dosage Ber-NS decreases blood glucose and improves lipid metabolism in type 2 diabetic C57BL/6 mice. These results suggest that the delivery of Ber as a nanosuspension is a promising approach for treating type 2 diabetes.
Collapse
|
118
|
Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies. Eur J Pharm Sci 2015; 69:51-60. [DOI: 10.1016/j.ejps.2014.11.012] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2014] [Revised: 09/25/2014] [Accepted: 11/09/2014] [Indexed: 11/21/2022]
|
119
|
Abouelmagd SA, Sun B, Chang AC, Ku YJ, Yeo Y. Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right? Mol Pharm 2015; 12:997-1003. [PMID: 25658769 DOI: 10.1021/mp500817h] [Citation(s) in RCA: 157] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
In vitro drug release kinetics studies are routinely performed to examine the ability of new drug formulations to modulate drug release. The underlying assumption is that the studies are performed in a sufficiently dilute solution, where the drug release is not limited by the solubility and the difference in release kinetics profile reflects the performance of a drug carrier in vivo. This condition is, however, difficult to meet with poorly water-soluble drug formulations, as it requires a very large volume of release medium relative to the formulation mass, which makes it challenging to measure the drug concentration accurately. These difficulties are aggravated with nanoparticle (NP) formulations, which are hard to separate from the release medium and thus require a dialysis bag or repeated high-speed centrifugation for sampling. Perhaps for these reasons, drug release kinetics studies of NPs of poorly water-soluble drugs are often performed in suboptimal conditions in which the NPs are not sufficiently diluted. However, such a practice can potentially underestimate drug release from NPs, leading to an inaccurate prediction that the NPs will attenuate the drug activity in vivo. Here we perform release kinetics studies of two different NP formulations of paclitaxel, a representative poorly water-soluble drug, according to common practices in the literature. We find that the drug release from NPs can be substantially underestimated depending on the choice of the release medium, NP/medium ratio, and handling of release samples. We discuss potential consequences of underestimating drug release, ending with suggestions for future studies with NP formulations of poorly water-soluble drugs.
Collapse
Affiliation(s)
- Sara A Abouelmagd
- Department of Industrial and Physical Pharmacy and ‡Weldon School of Biomedical Engineering, Purdue University , West Lafayette, Indiana 47907, United States
| | | | | | | | | |
Collapse
|
120
|
Bartlett JA, Brewster M, Brown P, Cabral-Lilly D, Cruz CN, David R, Eickhoff WM, Haubenreisser S, Jacobs A, Malinoski F, Morefield E, Nalubola R, Prud’homme RK, Sadrieh N, Sayes CM, Shahbazian H, Subbarao N, Tamarkin L, Tyner K, Uppoor R, Whittaker-Caulk M, Zamboni W. Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks. AAPS J 2015; 17:44-64. [PMID: 25421459 PMCID: PMC4287304 DOI: 10.1208/s12248-014-9701-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 11/08/2014] [Indexed: 01/26/2023] Open
Abstract
At the Product Quality Research Institute (PQRI) Workshop held last January 14-15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of characterization, formulation development, manufacturing, and nonclinical safety evaluation of nanomaterial-containing drug products for human use. The workshop discussions identified areas where additional understanding of material attributes, absorption, biodistribution, cellular and tissue uptake, and disposition of nanosized particles would continue to inform their safe use in drug products. Analytical techniques and methods used for in vitro characterization and stability testing of formulations containing nanomaterials were discussed, along with their advantages and limitations. Areas where additional regulatory guidance and material characterization standards would help in the development and approval of nanomedicines were explored. Representatives from the US Food and Drug Administration (USFDA), Health Canada, and European Medicines Agency (EMA) presented information about the diversity of nanomaterials in approved and newly developed drug products. USFDA, Health Canada, and EMA regulators discussed the applicability of current regulatory policies in presentations and open discussion. Information contained in several of the recent EMA reflection papers was discussed in detail, along with their scope and intent to enhance scientific understanding about disposition, efficacy, and safety of nanomaterials introduced in vivo and regulatory requirements for testing and market authorization. Opportunities for interaction with regulatory agencies during the lifecycle of nanomedicines were also addressed at the meeting. This is a summary of the workshop presentations and discussions, including considerations for future regulatory guidance on drug products containing nanomaterials.
Collapse
Affiliation(s)
| | - Marcus Brewster
- />Janssen Pharmaceutica, Johnson and Johnson, Beerse, Belgium
| | - Paul Brown
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | | | - Celia N. Cruz
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
- />United States Food and Drug Administration, 10903 New Hampshire Ave., Rm. 4142 Bldg. 51, Silver Spring, Maryland 20993 USA
| | - Raymond David
- />BASF Corporation, Ecology and Safety, Florham Park, New Jersey 07932 USA
| | | | | | - Abigail Jacobs
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - Frank Malinoski
- />Nanomedicines Alliance, Washington, District of Columbia USA
| | - Elaine Morefield
- />Vertex Pharmaceuticals Incorporated, Boston, Massachusetts 02210 USA
| | - Ritu Nalubola
- />Office of the Commissioner, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - Robert K. Prud’homme
- />Chemical and Biological Engineering, School of Engineering and Applied Science, Princeton University, Princeton, New Jersey 08544 USA
| | - Nakissa Sadrieh
- />Center for Food Safety and Applied Nutrition, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - Christie M. Sayes
- />RTI International, Research Triangle Park, North Carolina 27709 USA
| | | | - Nanda Subbarao
- />Biologics Consulting Group, Alexandria, Virginia 22314 USA
| | | | - Katherine Tyner
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - Rajendra Uppoor
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - Margaret Whittaker-Caulk
- />Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20903 USA
| | - William Zamboni
- />UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, University of North Carolina, Chapel Hill, North Carolina 27514 USA
- />Wildcat Pharmaceutical Development Center, Houston, Texas 77389 USA
| |
Collapse
|
121
|
Nanosizing: “End-to-End” Formulation Strategy for Poorly Water-Soluble Molecules. DISCOVERING AND DEVELOPING MOLECULES WITH OPTIMAL DRUG-LIKE PROPERTIES 2015. [DOI: 10.1007/978-1-4939-1399-2_13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
|
122
|
Affiliation(s)
- Kunikazu Moribe
- Department of Pharmaceutical Technology, Graduate School of Pharmaceutical Sciences, Chiba University
| | - Kenjirou Higashi
- Department of Pharmaceutical Technology, Graduate School of Pharmaceutical Sciences, Chiba University
| |
Collapse
|
123
|
Wei L, Ji Y, Gong W, Kang Z, Meng M, Zheng A, Zhang X, Sun J. Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals. Drug Dev Ind Pharm 2014; 41:1343-52. [PMID: 25156484 DOI: 10.3109/03639045.2014.950272] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Paclitaxel (PTX) is a natural broad-spectrum anticancer drug with poor aqueous solubility. PTX nanocrystals were formulated to improve the water solubility, and PTX nanosuspensions were prepared using anti-solvent precipitation, and then organic solvent and surfactants were removed by filtering through a vacuum system. The physical characterization of PTX nanocrystals were measured by transmission electron microscope, X-ray diffraction and differential scanning calorimetry. In addition, saturation solubility, in vitro release, stability and pharmacokinetic characteristics were examined. The average particle size of PTX nanocrystals was ∼200 nm, and they had a stable potential and a uniform distribution. Paclitaxel nanocrystals can effectively improve drug solubility and in vitro release. PTX pharmacokinetic and tissue distribution studies were compared after intravenous administration of nanocrystals versus a commercial injection formulation. PTX nanocrystals were rapidly distributed with a longer elimination phase. Moreover, tissue distribution indicated that PTX nanocrystals are mainly absorbed by the liver and spleen and may offer reduced renal and cardiovascular toxicity which may reduce side effects.
Collapse
Affiliation(s)
- Lisha Wei
- Department of Pharmaceutics, Beijing Institute of Pharmacology and Toxicology , Beijing , P.R. China
| | | | | | | | | | | | | | | |
Collapse
|
124
|
Zhang Y, Che E, Zhang M, Sun B, Gao J, Han J, Song Y. Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths. Int J Pharm 2014; 473:375-83. [PMID: 25051114 DOI: 10.1016/j.ijpharm.2014.07.024] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Accepted: 07/18/2014] [Indexed: 01/17/2023]
Abstract
In the present study, a novel hierarchical porous carbon monolith (HPCM) with three-dimensionally (3D) ordered macropores (∼ 400 nm) and uniform accessible mesopores (∼ 5.2 nm) was synthesized via a facile dual-templating technique using colloidal silica nanospheres and Poloxamer 407 as templates. The feasibility of the prepared HPCM for oral drug delivery was studied. Valsartan (VAL) was chosen as a poorly water-soluble model drug and loaded into the HPCM matrix using the solvent evaporation method. Scanning electron microscopy (SEM) and specific surface area analysis were employed to characterize the drug-loaded HPCM-based formulation, confirming the successful inclusion of VAL into the nanopores of HPCM. Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) demonstrated that the incorporated drug in the HPCM matrix was in an amorphous state and the VAL formulation exhibited good physical stability for up to 6 months. In vitro tests showed that the dissolution rate of HPCM-based formulation was increased significantly compared with that of crystalline VAL or VAL-loaded 3D ordered macroporous carbon monoliths (OMCMs). Furthermore, a pharmacokinetic study in rats demonstrated about 2.4-fold increase in oral bioavailability of VAL in the case of HPCM-based formulation compared with the commercially available VAL preparation (Valzaar(®)). These results therefore suggest that HPCM is a promising carrier able to improve the dissolution rate and oral bioavailability of the poorly water-soluble drug VAL.
Collapse
Affiliation(s)
- Yanzhuo Zhang
- School of Pharmacy, Xuzhou Medical College, Xuzhou 221004, China.
| | - Erxi Che
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Miao Zhang
- Pharmaceutical Division, Jiangsu Hengrui Pharma,Lianyungang 222047, China
| | - Baoxiang Sun
- Pharmaceutical Division, Jiangsu Hengrui Pharma,Lianyungang 222047, China
| | - Jian Gao
- School of Pharmacy, Xuzhou Medical College, Xuzhou 221004, China
| | - Jin Han
- School of Pharmacy, Xuzhou Medical College, Xuzhou 221004, China
| | - Yaling Song
- School of Pharmacy, Xuzhou Medical College, Xuzhou 221004, China
| |
Collapse
|
125
|
Rambharose S, Ojewole E, Branham M, Kalhapure R, Govender T. High-energy ball milling of saquinavir increases permeability across the buccal mucosa. Drug Dev Ind Pharm 2014; 40:639-48. [DOI: 10.3109/03639045.2014.884120] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
126
|
Zhu L, Yang S, Qu X, Zhu F, Liang Y, Liang F, Wang Q, Li J, Li Z, Yang Z. Fibril-shaped aggregates of doxorubicin with poly-l-lysine and its derivative. Polym Chem 2014. [DOI: 10.1039/c4py00686k] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Doxorubicin forms fibril-like aggregates in phosphate buffer and complexes with poly-l-lysine and cholate-grafted poly-l-lysine.
Collapse
Affiliation(s)
- Lijun Zhu
- University of Chinese Academy of Sciences
- Beijing 100049, China
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
| | - Saina Yang
- University of Chinese Academy of Sciences
- Beijing 100049, China
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
| | - Xiaozhong Qu
- University of Chinese Academy of Sciences
- Beijing 100049, China
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
| | - Feiyan Zhu
- University of Chinese Academy of Sciences
- Beijing 100049, China
| | - Yongri Liang
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| | - Fuxin Liang
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| | - Qian Wang
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| | - Jiaoli Li
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| | - Zhibo Li
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| | - Zhenzhong Yang
- State Key Laboratory of Polymer Physics and Chemistry
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190, China
| |
Collapse
|
127
|
Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. Colloids Surf B Biointerfaces 2013; 111:277-81. [DOI: 10.1016/j.colsurfb.2013.06.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 05/18/2013] [Accepted: 06/04/2013] [Indexed: 11/18/2022]
|
128
|
Hasa D, Voinovich D, Perissutti B, Grassi G, Fiorentino S, Farra R, Abrami M, Colombo I, Grassi M. Reduction of melting temperature and enthalpy of drug crystals: Theoretical aspects. Eur J Pharm Sci 2013; 50:17-28. [DOI: 10.1016/j.ejps.2013.03.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2012] [Revised: 03/21/2013] [Accepted: 03/22/2013] [Indexed: 10/27/2022]
|